Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.35 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269134 | 1.00 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2265884 | 0.72 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2269127 | 0.72 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28779402 | 0.71 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3511589 | 0.71 | SLC22A2 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7715116 | 0.71 | ALDH1A1 (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6837069 | 0.71 | SLC22A2 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL11637716 | 0.70 | MAPT (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6679868 | 0.69 | ALDH1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL839163 | 0.69 | ALDH1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | disclosed |
| EP-1188768-B1 | LHRH antagonist peptides | UNIV INDIANA RES & TECH CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-7071165-B2 | LHRH antagonist peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6455499-B1 | Methods for treating disorders associated with LHRH activity | INDIANA UNIVERSITY FOUNDATION | 2002-09-24 | — | — | US | disclosed |
| EP-0794961-B1 | LHRH ANTAGONIST PEPTIDES | ADVANCED RES & TECH INST (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6423686-B1 | LHRH antagonist peptides | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE | 2002-07-23 | — | — | US | disclosed |
| EP-1188768-A2 | LHRH antagonist peptides | Advanced Research & Technology Institute (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-0794961-A2 | LHRH ANTAGONIST PEPTIDES | INDIANA UNIVERSITY FOUNDATION (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996040757-A2 | LHRH ANTAGONIST PEPTIDES | INDIANA UNIVERSITY FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5300492-A | Suppressing levels of sex hormones in male or female mammals | TAP PHARMACEUTICALS (US) | 1994-04-05 | — | — | US | disclosed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | GRIN2D 59/4885GRIN3B 5/4885GRIN1 2/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | GRIN2D 59/4885GRIN3B 5/4885GRIN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.